Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 7386.

https://doi.org/10.1182/blood-2025-7386

Published: 2025

Journal Articles

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 7032.

https://doi.org/10.1182/blood-2025-7032

Published: 2025

Journal Articles

AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

Sarvarinder Gill, Maher Albitar, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2025-1731

Published: 2025

Journal Articles

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Blood (2025) 146 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2025-3617

Published: 2025

Journal Articles

Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Behzad Amoozgar, Ayrton I Bangolo, David H. Vesole, David S. Siegel, Noa Biran, Pooja Phull, Michele L. Donato, Harsh Parmar

Blood (2024) 144 (Supplement 1): 2408.

https://doi.org/10.1182/blood-2024-211671

Published: 2024

Journal Articles

Evaluating the Survival Impact of Different Treatment Modalities in Gastric Marginal Zone Lymphoma Based on Tumor Stage: A SEER Database Analysis

Ayrton I Bangolo, Lili Zhang, Vignesh K Nagesh, Andrew Ip, Behzad Amoozgar

Blood (2024) 144 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2024-202424

Published: 2024

Journal Articles

Real World Outcomes of Multiple Myeloma Patients Who Underwent Apheresis for Planned Chimeric Antigen Receptor (CAR) T Cell Therapy: A Single Center Experience

Ayrton I Bangolo, Sarvarinder Kaur Gill, Behzad Amoozgar, Shraboni Dey, Ronit Slotky, David S. Siegel, Harsh Parmar, Noa Biran, David H. Vesole, Pooja Phull

Blood (2024) 144 (Supplement 1): 7097.

https://doi.org/10.1182/blood-2024-211895

Published: 2024

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2023-182204

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

David Qualls, Michael J Buege, Phuong Dao, Paolo F. Caimi, Sarah C. Rutherford, Graham Wehmeyer, Jason T. Romancik, Lori A. Leslie, Mwanasha H. Merrill, Jennifer L. Crombie, Behzad Amoozgar, Brad S. Kahl, David A. Bond, Kami J. Maddocks, Michelle Okwali, Venkatraman Seshan, Gilles Salles, Connie Lee Batlevi

Blood (2022) 140 (Supplement 1): 787–789.

https://doi.org/10.1182/blood-2022-167620

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Evaluating the Survival Impact of Different Treatment Modalities in Gastric Marginal Zone Lymphoma Based on Tumor Stage: A SEER Database Analysis

Real World Outcomes of Multiple Myeloma Patients Who Underwent Apheresis for Planned Chimeric Antigen Receptor (CAR) T Cell Therapy: A Single Center Experience

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only